WO2004004689A8 - Compositions and methods for amelioration of human female sexual dysfunction - Google Patents

Compositions and methods for amelioration of human female sexual dysfunction

Info

Publication number
WO2004004689A8
WO2004004689A8 PCT/US2003/020779 US0320779W WO2004004689A8 WO 2004004689 A8 WO2004004689 A8 WO 2004004689A8 US 0320779 W US0320779 W US 0320779W WO 2004004689 A8 WO2004004689 A8 WO 2004004689A8
Authority
WO
WIPO (PCT)
Prior art keywords
female sexual
sexual dysfunction
methods
compositions
amelioration
Prior art date
Application number
PCT/US2003/020779
Other languages
French (fr)
Other versions
WO2004004689A1 (en
Inventor
James L Yeager
Nadir Bueyuektimkin
Servet Bueyuektimkin
Mingqi Lu
Y Joseph Mo
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Priority to CA002489563A priority Critical patent/CA2489563A1/en
Priority to EP03763097A priority patent/EP1517672A1/en
Priority to EA200500126A priority patent/EA008720B1/en
Priority to JP2004519748A priority patent/JP2005535658A/en
Priority to NZ537276A priority patent/NZ537276A/en
Priority to AU2003248785A priority patent/AU2003248785A1/en
Publication of WO2004004689A1 publication Critical patent/WO2004004689A1/en
Publication of WO2004004689A8 publication Critical patent/WO2004004689A8/en
Priority to NO20045534A priority patent/NO20045534L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Abstract

The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In one embodiment, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a penetration enhancer, a polymer thickener, a lipophilic component, and an acidic buffer system.
PCT/US2003/020779 1998-12-10 2003-07-02 Compositions and methods for amelioration of human female sexual dysfunction WO2004004689A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002489563A CA2489563A1 (en) 2002-07-02 2003-07-02 Compositions and methods for amelioration of human female sexual dysfunction
EP03763097A EP1517672A1 (en) 2002-07-02 2003-07-02 Compositions and methods for amelioration of human female sexual dysfunction
EA200500126A EA008720B1 (en) 1998-12-10 2003-07-02 Use of a prostaglandin-based composition for amelioration of human female sexual dysfunction
JP2004519748A JP2005535658A (en) 2002-07-02 2003-07-02 Compositions and methods for improving sexual dysfunction in human women
NZ537276A NZ537276A (en) 2002-07-02 2003-07-02 Topical compositions containing a vasoactive prostaglandin for amelioration of human female sexual dysfunction
AU2003248785A AU2003248785A1 (en) 2002-07-02 2003-07-02 Compositions and methods for amelioration of human female sexual dysfunction
NO20045534A NO20045534L (en) 2002-07-02 2004-12-17 Compositions and methods for the relief of human female sexual dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/188,554 US6825234B2 (en) 1998-12-10 2002-07-02 Compositions and methods for amelioration of human female sexual dysfunction
US10/188,554 2002-07-02

Publications (2)

Publication Number Publication Date
WO2004004689A1 WO2004004689A1 (en) 2004-01-15
WO2004004689A8 true WO2004004689A8 (en) 2004-04-15

Family

ID=30114011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020779 WO2004004689A1 (en) 1998-12-10 2003-07-02 Compositions and methods for amelioration of human female sexual dysfunction

Country Status (10)

Country Link
US (1) US6825234B2 (en)
EP (1) EP1517672A1 (en)
JP (1) JP2005535658A (en)
CN (1) CN1665485A (en)
AU (1) AU2003248785A1 (en)
CA (1) CA2489563A1 (en)
NO (1) NO20045534L (en)
NZ (1) NZ537276A (en)
WO (1) WO2004004689A1 (en)
ZA (1) ZA200410009B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
AU2004224459A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Angiogenesis promotion by prostaglandin compositions and methods
CA2520347A1 (en) * 2003-04-02 2004-10-21 Nexmed Holdings, Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050239742A1 (en) * 2004-04-08 2005-10-27 Vivus, Inc. Carrageenan-based formulations and associated methods of use
KR100558012B1 (en) * 2004-07-16 2006-03-06 삼성전자주식회사 Semiconductor memory devices
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
AU2006330846A1 (en) * 2005-12-27 2007-07-05 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
BR112013025744A2 (en) 2011-04-07 2016-08-16 Nexmed Holdings Inc Raynaud's disease treatment compositions
TW201431572A (en) 2012-12-21 2014-08-16 Teikoku Pharma Usa Inc Compositions and methods for transdermal delivery of hormones and other medicinal agents

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3852465A (en) 1972-09-21 1974-12-03 Upjohn Co Abortion by myometrial administration of prostaglandins
US4005221A (en) 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4217360A (en) 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4043339A (en) 1976-02-02 1977-08-23 The Upjohn Company Method of and vaginal insert for prostaglandin administration
JPS52156913A (en) 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
AU519132B2 (en) 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
JPS5573676A (en) 1978-11-30 1980-06-03 Ono Pharmaceut Co Ltd Simulated compound of prostaglandin i2 and its preparation
JPS5589297A (en) 1978-12-28 1980-07-05 Kureha Chem Ind Co Ltd Prostaglandin derivative, its preparation and its drug
SE431821B (en) 1979-01-29 1984-03-05 Perstorp Ab STORAGE STABLE, PROSTAGLANDIN-CONTAINING MEDICAL PREPARATION
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
USRE30439E (en) 1979-03-12 1980-11-25 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4317447A (en) 1979-07-19 1982-03-02 Ortho Pharmaceutical Corporation Drug delivery system
US4318908A (en) 1979-12-06 1982-03-09 Kureha Kagaku Kogyo Kabushiki Kaisha Methylated prostaglandin derivatives
US4289785A (en) 1980-08-06 1981-09-15 The Upjohn Company Method and compositions involving prostaglandins
ZA831186B (en) 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4515810A (en) 1983-10-06 1985-05-07 American Cyanamid Company Composition of matter
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US4771004A (en) 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
EP0266968A3 (en) 1986-11-03 1988-08-24 Gérard G. Cohen Gelled ointment of vasodilating agent
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
JPS63135333A (en) 1986-11-26 1988-06-07 Nitto Electric Ind Co Ltd Plaster containing prostaglandins
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
IT1221826B (en) 1988-06-08 1990-07-12 Medico Harvey Srl Centro PREPARED FOR TOPICAL USE FOR THE THERAPEUTIC TREATMENT OF IMPOTENTIA COEUNDI
SE463851B (en) 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
JP2910857B2 (en) 1989-04-04 1999-06-23 ニチバン株式会社 Prostaglandin E1 transdermal preparation
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
CA2352552C (en) 1990-04-25 2008-12-02 Virgil A. Place Treatment of erectile dysfunction
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5981593A (en) 1991-07-03 1999-11-09 Scott; Nathan Earl Prostaglandin E2 treatment of impotence
WO1993000894A1 (en) 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US6291528B1 (en) 1991-07-03 2001-09-18 Nathan Earl Scott Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
AU658681B2 (en) 1991-10-23 1995-04-27 Block Drug Company Inc., The Penetration enhancement of topically applied formulations
CA2123007A1 (en) 1991-11-08 1993-05-13 Ken-Ichi Nishimura Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration
BR9203277A (en) 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum USE OF ERETOGENIC DRUGS AND THEIR APPLICATION METHODOLOGIES
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5324746A (en) 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
AU5358896A (en) 1995-03-14 1996-10-02 Vivus, Inc. Method and kit for preventing erectile dysfunction
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
DK0934078T3 (en) * 1996-10-24 2003-04-14 Alza Corp Permeability promoters for transdermal administration of active substances, devices and processes for their preparation
GR1002847B (en) 1997-05-06 1998-01-27 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
US20020004529A1 (en) 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
AU1827299A (en) 1997-12-18 1999-07-05 Nathan Earl Scott Prostaglandin e2/f2alpha combination for treating impotence and enhancing sexual arousal
US6046240A (en) 1998-05-01 2000-04-04 Harvard Scientific Corporation Methods for treating female sexual dysfunction
US6031002A (en) 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6403658B1 (en) 2000-09-21 2002-06-11 Shaina Toppo Genital vasodilator

Also Published As

Publication number Publication date
ZA200410009B (en) 2006-06-28
NO20045534L (en) 2005-03-01
US20030129241A1 (en) 2003-07-10
AU2003248785A1 (en) 2004-01-23
EP1517672A1 (en) 2005-03-30
CA2489563A1 (en) 2004-01-15
CN1665485A (en) 2005-09-07
JP2005535658A (en) 2005-11-24
NZ537276A (en) 2007-06-29
US6825234B2 (en) 2004-11-30
WO2004004689A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
WO2000033825A3 (en) Compositions and methods for amelioration of human female sexual dysfunction
WO2004004689A8 (en) Compositions and methods for amelioration of human female sexual dysfunction
CA2420895A1 (en) Method for treating erectile dysfunction and increasing libido in men
WO2004037173A3 (en) Method for treating erectile dysfunction and increasing libido in men
GEP20063982B (en) Use of prostaglandin compositions with male persons for treatment of erectile dysfunction
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2007044976A3 (en) Improved testosterone gel and method of use
WO2004108157A3 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
TW200603807A (en) Method for the treatment of premenstrual and other female sexual disorders
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
WO2004035747A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
EP1561457A3 (en) Cosmetic compositions with long lasting skin moisturizing properties
WO2004039247A3 (en) Compositions and methods for pain reduction
WO2003045434A3 (en) Endothelin antagonists ina method and composition for potentiating an opiate analgesic
WO2009015014A3 (en) Multi-step method of pain and/or inflammation treatment
SI1581235T1 (en) Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia
WO2005037347A3 (en) Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
WO2005041878A3 (en) Compositions and methods for increasing hdl and hdl-2b levels
WO2002098362A3 (en) Use of rank antagonists to treat cancer
AU2002253018A1 (en) Skin composition for reducing skin oils and grease
WO2003090688A3 (en) Enhancement of human epidermal melanogenesis
WO2002041832A8 (en) Compositions having comfrey and methods for reducing retinoid-induced skin irritation
BRPI0416202A (en) phosphodiesterase inhibitor formulations v

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 03/2004 UNDER (72) REPLACE "MO, J., JOSEPH" BY "MO, Y., JOSEPH"

WWE Wipo information: entry into national phase

Ref document number: 2004/10009

Country of ref document: ZA

Ref document number: 200410009

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2489563

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 537276

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004519748

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038155354

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020047021702

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003763097

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003248785

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200500126

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020047021702

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003763097

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003763097

Country of ref document: EP